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Abstract
Purpose: We have initiated a multi-institutional phase I trial of 5-fraction stereotac-
tic body radiotherapy (SBRT) for Stage III–IVa laryngeal cancer. We conducted this
pilot dosimetric study to confirm potential utility of online adaptive replanning to
preserve treatment quality.
Methods: We evaluated ten cases: five patients enrolled onto the current trial and
five patients enrolled onto a separate phase I SBRT trial for early-stage glottic larynx
cancer. Baseline SBRT treatment plans were generated per protocol. Daily cone-
beam CT (CBCT) or diagnostic CT images were acquired prior to each treatment
fraction. Simulation CT images and target volumes were deformably registered to
daily volumetric images, the original SBRT plan was copied to the deformed images
and contours, delivered dose distributions were re-calculated on the deformed CT
images. All of these were performed on a commercial treatment planning system.
In-house software was developed to propagate the delivered dose distribution back
to reference CT images using the deformation information exported from the treat-
ment planning system. Dosimetric differences were evaluated via dose-volume
histograms.
Results: We could evaluate dose within 10 minutes in all cases. Prescribed cover-
age to gross tumor volume (GTV) and clinical target volume (CTV) was uniformly
preserved; however, intended prescription dose coverage of planning treatment vol-
ume (PTV) was lost in 53% of daily treatments (mean: 93.9%, range: 83.9–
97.9%). Maximum bystander point dose limits to arytenoids, parotids, and spinal
cord remained respected in all cases, although variances in carotid artery doses
were observed in a minority of cases.
Conclusions: Although GTV and CTV SBRT dose coverage is preserved with in-
room three-dimensional image guidance, PTV coverage can vary significantly from
intended plans and dose to critical structures may exceed tolerances. Online adap-
tive treatment re-planning is potentially necessary and clinically applicable to fully
preserve treatment quality. Confirmatory trial accrual and analysis remains ongoing.
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1 | INTRODUCTION
Squamous cell carcinoma of the larynx is common in North
America.1 Organ preservation with chemoradiotherapy represents
standard-of-care for locally advanced disease.2,3 Conventional tech-
niques deliver 70 Gy over 7 weeks with incidental coverage of unin-
volved larynx and healthy bystander tissues. Long-term outcomes
from RTOG 91-11 demonstrated comparable larynx preservation and
overall survival with sequential or concurrent chemoradiotherapy.4 A
discouraging finding from this trial was that improved organ preser-
vation with concurrent chemoradiotherapy came at the cost of late
deaths, potentially due to undetected toxicity. Since this trial, no sig-
nificant advances have been made in radiation-based organ preserva-
tion strategies for advanced larynx cancer.
Accelerated hypofractionated irradiation of early-stage larynx
cancer originated in Europe, with early results mirroring those
achieved with conventional therapy.5,6 Despite conventional radia-
tion techniques, there was no difference in cure rates when reducing
radiation therapy from a 5-week course down to 3 weeks.7 Later, a
British Institute of Radiology study showed equivalent survival rates
and no significant differences in toxicity with either a 3-week or
6-week radiation course.6 More recently, the Royal Marsden Hospi-
tal treated 200 patients with T1 glottic cancer to a dose of 50–
52.5 Gy in 16 daily fractions,5 matching outcomes from historical
studies. Beyond patient convenience and cost-saving advantages,
hypofractionated radiation therapy may improve local control rates.8
A phase III clinical trial showed improved local control with
56.25 Gy in 25 fractions compared to 60–66 Gy in 30–33 fractions,
with equivalent toxicity.9
We have initiated a multi-institutional phase I trial of 5-fraction
stereotactic body radiotherapy (SBRT) for Stage III–IVa laryngeal can-
cer. SBRT divides intended radiation dose into five or fewer fractions
with steep dose gradients and tight treatment accuracy constraints.
Thus, SBRT employs dramatically higher daily doses than conven-
tional therapy, and holds promise for improving outcomes for high-
risk disease. For example, local control of early-stage lung cancer
with conventional radiation treatment is less than 50%, while newer
series employing SBRT demonstrate improved local control approxi-
mating 90%.10–12
Current radiation delivery techniques are based on a planning CT
scan acquired before therapy begins, without planned changes dur-
ing treatment. The geometry of tumor and normal anatomy can shift
significantly secondary to movement and tissue responses. Serial CT
studies taken during standard treatment demonstrate that tumors
can shrink by > 90% during a 7-week course of treatment, and that
parotid glands can involute and shift by up to a centimeter.13 Adap-
tive replanning techniques have been leveraged to correct for these
changes and are evolving toward becoming a routine component of
standard-of-care.14,15 To our knowledge, there are no published
reports describing dosimetric variances which take place during
accelerated hypofractionated treatment of head and neck cancer. In
this report, we describe post hoc calculation of dose variances and
pilot validation of an online adaptive planning platform to preserve
treatment quality in a series of ten patients treated on prospective
institutional clinical trials formally investigating SBRT for definitive
treatment of laryngeal cancer.
2 | METHODS
For this pilot analysis we included five patient cases (Pt# 6–10)
enrolled onto an advanced stage SBRT dose searching phase I trial
(NCT02464137) and five patients (Pt# 1–5) enrolled onto a separate
phase I SBRT trial for early-stage disease (NCT01984502). All ten
patients were treated at the same institution and their data were
analyzed identically. Patient characteristics are described in Table 1.
Gross Tumor Volume (GTV) was defined as all known gross disease
determined by examination, CT, MRI, and FDG-PET images. All
equivocal radiographic abnormalities, such as clinically suspicious
lymph nodes, were included within GTV. The Clinical Target Volumes
(CTV) was defined as the GTV plus areas at risk for adjacent spreads
of microscopic disease. The circumferential margin between primary
GTV and its CTV was 0.5 cm. Circumferential margin around nodal
GTVs and their CTVs was 1.0 cm. Per treatment protocol, unin-
volved nodal stations were not targeted for prophylactic coverage,
regardless of stage. Planning Target Volume (PTV) provided circum-
ferential margin of 2 mm around each CTV to compensate for the
variability in treatment set up and internal organ motion. All patients
were prescribed 42.5 Gy to D95% of the PTV in 5 fractions.
Avoidance structures included brainstem, spinal cord, parotid
gland, carotid artery, and arytenoid cartilage. The spinal cord and the
TAB L E 1 Study Cohort Characteristics.
Patient # Gender Age Primary site Stage GTV (cm3)
1 M 63 Glottic larynx T1aN0 0.13
2 M 59 Glottic larynx T2N0 6.49
3 M 79 Glottic larynx T2N0 7.90
4 M 39 Glottic larynx T1aN0 0.88
5 M 70 Glottic larynx T2N0 3.08
6 M 75 Supraglottic larynx T3N0 11.40
7 F 87 Glottic larynx T4N0 12.10
8 M 78 Glottic larynx T4N0 4.80
9 M 57 Glottic larynx T3N0 8.20
10 M 68 Glottic larynx T3N0 6.08
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brainstem were expanded 5 mm to create a planning organ at risk
volume (PRV). The maximum dose to spinal cord/brainstem, con-
tralateral arytenoid, and contralateral carotid could not exceed
10 Gy, 21.4 Gy, 26.9 Gy, respectively. Maximum doses were calcu-
lated from a 0.035 cm3 subvolume. Mean dose to parotids could not
exceed 26 Gy.
We have established a SBRT quality assurance (QA) procedure
to evaluate SBRT treatment delivery. All treatment planning and
treatment delivery evaluation was performed with a commercial
planning system (Eclipse v.11; Varian Medical Systems, Palo Alto,
CA, USA) combined with in-house software. Figure 1 illustrates a
flowchart for our SBRT QA and adaptive replanning platform. All
baseline SBRT treatment plans were generated in Eclipse per proto-
col directives. Figure 2 demonstrates images collected at specific
phases along our adaptive replanning process from a representative
case. Thermoplastic masks were used to immobilize patients from
CT simulation to every fraction of treatment. The number of days
between CT simulation to the first fraction of treatment varies from
3 to 33 days (average = 15.6 days). The number of days between
consecutive fractions of treatment varies from 2 to 5 days with an
average of 2.8 days. For one patient (#3) with travel issues there
was an 11 day interval between the first and second fraction of
treatment. Daily cone-beam CT (CBCT) for Patients 6–10 or conven-
tional fan-beam CT images for Patients 1–5 were acquired prior to
every treatment fraction. Reference simulation CT images and target
volumes were deformably registered to daily images via commercially
available software (SmartAdapt; Varian Medical Systems, Palo Alto,
CA, USA). SmartAdapt uses “accelerated demons” algorithm.16
Figs. 2(g)–2(i) demonstrate an example of our deformable image reg-
istration results. A board-certified medical physicist and a physician
reviewed the registration results. The deformed simulation CT and
contours were exported and reloaded in the Eclipse system and the
reference SBRT plan was directly copied to deformed images and
segmented volumes in Eclipse. Isocenters were always defined at
mass centers of PTVs, and were shifted according to patient setup
errors or deformably corrected daily imaging. Delivered dose distri-
butions were obtained by re-calculating doses on deformed CT
images in Eclipse with Anisotropic Analytical Algorithm (version
11.0.31). Dose distributions were visually reviewed by a physician
and a medical physicist. DVH curves were automatically checked by
in-house software in Matlab 2013b (Mathwork, Natick, MA, USA).
Any plan could be re-optimized with identical planning dosimetric
constraints in Eclipse.
We have developed an in-house software package to propagate all
delivered dose distribution back onto reference CT simulation images
to calculate cumulative doses. The package was developed first in
Matlab and then in Visual Studio C++ 2010 (Microsoft, Redmond, WA,
USA). The software loaded (1) dose distribution files, (2) reference
structure files, and (3) deformable image registration results in DICOM
format. It deformed radiation dose on 3 mm calculation grids from the
daily images to reference CT simulation images using the Eclipse regis-
tration results (grid size = 4 mm). Deformed doses on irregular grids
were resampled to a fine regular orthogonal grid using the half pixel
size of reference CT images (pixel size typically = 1.12 mm) to create
a dose-volume histogram (DVH). Deformed dose accuracy was vali-
dated via a commercially available system (Mirada DBx; Mirada
F I G . 1 . Adaptive replanning and SBRT QA flowchart.
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Medical USA, Denver, CO, USA). Mirada DBx loads reference simula-
tion CT images, deformed CT images, recalculated dose distributions
on deformed CT images, and deformable image registration results
from Eclipses. It then deforms recalculated dose distributions back
onto the reference CT images using Eclipse SmartAdapt registration
results. Three-dimensional Gamma analysis,17 maximum dose, DVH
curves comparisons were performed to compare results from our in-
house software with those from Mirada.
3 | RESULTS
Performance of our online adaptive SBRT QA platform was relevant
to the timeframe of routine clinical care. On average, for every frac-
tion of treatment the software required 3 minutes for deformable
image registration, 1 minute to map contours, 1.5 minutes for dose
re-calculation, about 1.5 minutes for data loading and exporting, and
about 3 minutes for re-planning. In sum, online adaptive replanning
was completed from initial data input to final data export within
10 minutes for each treatment.
We compared our deformed dose distribution with results from
commercial (Mirada) software via three-dimensional Gamma analysis.
For all fractions of delivery, the passing rate of 3% and 3 mm ranged
from 97.23 to 99.99% (mean = 99.71%) while the passing rate of
3% and 1 mm ranged from 97.06 to 99.99% (mean = 99.59%). Large
discrepancies occurred around the dose calculation boarders. The
dose calculation box remained rectangular in both the reference plan
and the adaptive replan in Miranda. To preserve efficiency, our in-
house software deforms representative tetrahedra containing the
patient body, yielding some irregular external surface/boarders. The
two algorithms also interpolate dose along calculation borders differ-
ently. In order to compare interpolation fidelity from dose calculation
grids to CT voxels, we benchmarked our post-deformation PTV
Dmax calculations to Mirada. PTV Dmax was obtained on three sets
of dose distributions, the delivered dose distribution (before the
dose deformation), and two sets of deformed dose distributions by
our dose deformation and Mirada method, separately. Detected dif-
ferences were considered errors. PTV Dmax error distributions for
each method are shown in Fig. 3. Average Dmax dose errors were
0.02 Gy using our platform while average Dmax errors were
(a) (b) (c)
(d) (e) (f)
(g) (h) (i)
(j) (k) (l)
(m) (n) (o)
F I G . 2 . A representative example of our adaptive treatment planning process. (a)–(c) axial, coronal, and sagittal views of reference dose
distribution on simulation CT images; (d)–(f) rigid image registration results; (g)–(i) deformable image registration results; (j)–(l) dose distribution
of reference plan directly delivered to the deformed sim CT; (m)–(o) dose distribution on deformed sim CT after re-planning.
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0.26 Gy for Mirada. DVH curves of deformed dose distributions
were slightly different. PTV coverage was compared via average
delivered PTV doses. Across all fractions of treatment, dose differ-
ences between our method and delivered dose ranged from
0.43 Gy to 0.50 Gy (mean = 0.06 Gy), while dose differences
between Mirada results and delivered plans varied from 0.82 Gy
to 0.07 Gy (mean = 0.26 Gy). PTV coverage deficiencies are sum-
marized in Fig. 4. Our system calculated an average daily PTV cover-
age deficiency of 1.5%, while the commercial system calculated an
average PTV coverage deficiency of 3.1%.
Delivered PTV dose coverage for all study cases were quantified
and compared with prescribed doses using an in-house Matlab pro-
gram. The protocol required prescription dose cover 95% of PTV.
Table 2 tabulates mean daily minimum, maximum, and average frac-
tional PTV, CTV, and GTV prescription dose coverage for each
patient. Prescribed treatment to GTV and CTVs was preserved in all
patients. The minimum daily prescription dose coverage of CTV was
93.8% and total average CTV coverage was 98.3%. However, inter-
fraction anatomic/set up changes led to loss of intended PTV dose
coverage during 53% of individual treatment fractions. The average
daily prescription dose coverage of PTV was 93.9% (range: 83.9–
98.7%). One case (patient #7) had a single treatment where coverage
of PTV dropped to 83.9%, although intended CTV coverage
remained above 96.9%. This patient demonstrated significant inter-
fraction motion. We could not reposition this patient for the first
treatment fraction, and we thus re-simulated the patient. A new ref-
erence plan based on the re-simulation CT was generated and deliv-
ered for all planned treatments while large interfracton motions still
occurred.
Mean cumulative dose coverage of CTV and GTV was 97.9%
(range: 95.2–99.5%) and 99.8% (range: 98.3–100.0%), respectively
(Table 3). Cumulative PTV dose coverage was less favorable across
the study cohort. Mean coverage of PTVs with prescribed dose was
92.7% (range: 86.1–96.1%). D95% PTV coverage was 39 Gy or
greater in all cases. Cumulative PTV VRx for Patient #7 was 86.1%.
F I G . 4 . Respective calculation of PTV coverage deficiencies with
our in-house (Deform) and commercial (Mirada) dose deformation
methods.
F I G . 3 . PTV Dmax error distributions resulting from our in-house
(Deform) and commercial (Mirada) dose deformation methods.
TAB L E 2 PTVs, CTVs, and GTVs daily dosimetric outcomes.
Patient #
PTV coverage CTV coverage GTV coverage
Min Max Avg Min Max Avg Min Max Avg
1 95.1% 97.9% 96.7% 97.8% 100.0% 99.1% 100.0% 100.0% 100.0%
2 96.2% 97.0% 96.6% 99.5% 99.9% 99.7% 100.0% 100.0% 100.0%
3 95.2% 96.9% 96.0% 99.6% 100.0% 99.7% 100.0% 100.0% 100.0%
4 93.2% 97.5% 96.0% 99.2% 100.0% 99.8% 100.0% 100.0% 100.0%
5 91.1% 95.6% 93.8% 99.4% 99.7% 99.5% 99.8% 100.0% 100.0%
6 88.6% 92.0% 90.6% 96.8% 97.8% 97.3% 100.0% 100.0% 100.0%
7 83.9% 92.1% 89.2% 96.9% 98.5% 97.6% 99.2% 100.0% 100.0%
8 91.0% 93.9% 92.6% 93.8% 94.5% 94.2% 99.3% 99.9% 99.7%
9 93.8% 97.8% 95.4% 97.0% 99.3% 98.1% 97.5% 99.0% 98.3%
10 90.9% 93.5% 92.4% 97.3% 98.2% 97.7% 99.6% 100.0% 99.8%
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Our patients came from two studies with different advanced
stages of cancer. Advanced stage disease (Pt# 6–10) with larger GTV
and disease spread outside the laryngeal cartilage indeed makes the
balance between PTV coverage and OAR sparing more challenging
to achieve. Figure 5 illustrates the PTV prescription dose coverage
as a function of GTV volume and it shows that coverage decreases
with GTV volume.
Changes in bystander dose delivery to organs at risk (OARs) are
detailed in Table 4. Maximum point dose and Dmean to arytenoids,
spinal cord, and parotids were well respected in all cases. Cumulative
Dmax to a single carotid artery increased by 13.9 Gy (patient #3)
and 6.5 Gy (patient #2) from intended doses in two patients. Dmax
> 45 Gy were observed for several OARs which overlapped with
PTV.
4 | DISCUSSION
Hypofractionation promises improved disease control (particularly
for advanced disease stage presentations), cost savings, and patient
convenience for definitive treatment of laryngeal cancer. Our find-
ings support continued prospective testing of adaptive replanning to
optimize the quality and safety of this approach. Dosimetric assess-
ment could be performed within 10 minutes and leveraged straight-
forward in-house software to supplement a commercially available
planning platform. Adaptive replanning can potentially prevent PTV
coverage failure along steep SBRT dose gradients in up to half of
cases.
SBRT requires tight geometric tolerances to maintain safety of
large fraction sizes and sharp dose gradients. Key priorities include
prevention of overdosing along unanticipated overlaps of adjoining
PTVs that drift toward one another, and prevention of underdosing
due to tumor migration out of a high dose target volume. Our
patients had in-room CBCT imaging performed prior to each frac-
tion for image-guided setup. Nonetheless, our post hoc dosimetric
analysis revealed that prescribed dose coverage to PTV was lost
during more than half of SBRT treatments. Correction of acute
dose deficiencies during individual fractions (as in the case of
patient #7) is unlikely with routine IGRT-based positional
TAB L E 3 Cumulative PTV, CTV, and GTV prescription dose
coverage.
Patient # PTV CTV GTV
1 94.9% 98.0% 100.0%
2 96.1% 99.5% 100.0%
3 95.2% 99.5% 100.0%
4 94.9% 99.0% 100.0%
5 93.0% 99.4% 100.0%
6 89.1% 95.6% 100.0%
7 86.1% 97.6% 99.9%
8 92.1% 95.2% 99.9%
9 95.1% 98.3% 98.3%
10 90.8% 97.4% 99.9%
F I G . 5 . Cumulative PTV coverage as a function of GTV volume.
TAB L E 4 Differences (Diff) between cumulative delivered (Cumul) and reference prescription doses (Ref) to organs at risk.
Pt #
Rt carotid
Dmax (Gy)
Lt carotid
Dmax (Gy)
Contral arytenoid
Dmax (Gy)
Spinal cord
Dmax (Gy)
Rt parotid
Dmean (Gy)
Lt parotid
Dmean (Gy)
Ref Cumul Diff Ref Cumul Diff Ref Cumul Diff Ref Cumul Diff Ref Cumul Diff Ref Cumul Diff
1 12.6 12.1 0.5 9.9 9.0 0.9 12.5 16.1 3.6 8.8 9.0 0.2 0.3 0.4 0.1 0.3 0.4 0.1
2 20.9 27.4 6.5 22.2 23.7 1.5 16.7 21.7 5.0 8.4 10.3 1.9 0.2 0.2 0.0 0.2 0.3 0.1
3 27.9 41.8 13.9 23.4 30.6 7.2 — — — 6.7 7.9 1.2 — — — — — —
4 13.4 15.6 2.2 7.3 7.9 0.6 14.0 14.4 0.4 8.1 8.1 0.1 — — — — — —
5 10.9 10.7 0.3 8.0 8.5 0.5 18.3 20.6 2.2 8.6 6.9 1.8 — — — — — —
6 16.8 17.7 0.9 15.1 14.2 0.9 22.3 19.0 3.4 5.7 4.8 0.9 — — — — — —
7 44.7 44.4 0.3 44.8 44.6 0.2 44.5 45.0 0.4 9.9 11.3 1.3 — — — — — —
8 13.2 16.1 2.9 12.1 12.0 0.1 45.1 45.6 0.5 8.1 8.9 0.8 0.4 0.4 0.0 0.3 0.3 0.0
9 13.1 13.1 0.0 43.3 42.1 1.1 45.1 44.8 0.4 7.8 7.8 0.1 0.5 0.5 0.0 0.8 1.1 0.3
10 23.7 23.6 0.1 20.4 19.7 0.7 45.3 44.6 0.6 2.3 2.0 0.3 0.4 0.3 0.0 0.3 0.3 0.0
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correction unaccompanied by replanning. Given that GTV and CTV
dose coverage was not lost in any case, the downstream clinical
consequences of PTV coverage deficiencies remain undefined.
Nonetheless, optimal therapeutic ratio requires preservation of
intended tumor coverage and sparing of neighboring OARs. We, in
fact, observed unanticipated Dmax dose increases to carotid arter-
ies and contralateral arytenoids in uncorrected cases where these
OARs bordered PTVs (Table 4). This potentially supports judicious
use of PRVs as a planning technique to protect specific critical
normal structures in individual cases, although adaptive replanning
would more globally address this and other longitudinal dosimetric
safety issues.
Taken together, our in-house ART software potentially provides
valid QA and treatment quality support at clinically relevant speed.
However, several factors yield uncertain impact on the platform’s
accuracy. First, the ideal algorithm to interpolate deformable image
registration and dose calculation results from a coarse grid (~4 mm)
to finer resolutions (~0.56 mm) remains unclear. Second, DVH calcu-
lations are dependent upon specific edge detection techniques used
to delineate volumes of interest;18 an optimal solution remains
unidentified. Third, inverse application of Eclipse’s deformable image
registration results may lead to further dose uncertainties.19 These
remain active areas of investigation for platform enhancement.
5 | CONCLUSIONS
Our online adaptive SBRT replanning platform appears accurate and
relevant to routine clinical care. Although GTV and CTV dose cover-
age can be preserved with CT-based IGRT guidance throughout a
course of hypofractionated treatment, PTV coverage can vary signifi-
cantly from intended plans. Use of online adaptive treatment re-
planning is potentially necessary and clinically feasible for preserving
the quality of head and neck SBRT. Formal validation of the feasibil-
ity and downstream clinical impact of adaptive replanning will
require continued prospective analysis. Patient accrual, dosimetric
analysis, and software refinement remain ongoing.
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